Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

930 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer.
Kruger S, Heinemann V, Ross C, Diehl F, Nagel D, Ormanns S, Liebmann S, Prinz-Bravin I, Westphalen CB, Haas M, Jung A, Kirchner T, von Bergwelt-Baildon M, Boeck S, Holdenrieder S. Kruger S, et al. Ann Oncol. 2018 Dec 1;29(12):2348-2355. doi: 10.1093/annonc/mdy417. Ann Oncol. 2018. PMID: 30346475 Free article.
Advances in cancer immunotherapy 2019 - latest trends.
Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, Schuebbe G, Renz BW, D'Haese JG, Schloesser H, Heinemann V, Subklewe M, Boeck S, Werner J, von Bergwelt-Baildon M. Kruger S, et al. J Exp Clin Cancer Res. 2019 Jun 19;38(1):268. doi: 10.1186/s13046-019-1266-0. J Exp Clin Cancer Res. 2019. PMID: 31217020 Free PMC article. Review.
Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled for lead time bias and waiting time paradox.
Kruger S, Schirle K, Haas M, Crispin A, Schirra J, Mayerle J, D'Haese JG, Kunz WG, Ricke J, Ormanns S, Kirchner T, Kobold S, Ilmer M, Gebauer L, Westphalen CB, von Bergwelt-Baildon M, Werner J, Heinemann V, Boeck S. Kruger S, et al. J Cancer Res Clin Oncol. 2020 Feb;146(2):391-399. doi: 10.1007/s00432-019-03061-4. Epub 2019 Oct 23. J Cancer Res Clin Oncol. 2020. PMID: 31642961
Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer.
Mahajan UM, Goni E, Langhoff E, Li Q, Costello E, Greenhalf W, Kruger S, Ormanns S, Halloran C, Ganeh P, Marron M, Lämmerhirt F, Zhao Y, Beyer G, Weiss FU, Sendler M, Bruns CJ, Kohlmann T, Kirchner T, Werner J, D'Haese JG, von Bergwelt-Baildon M, Heinemann V, Neoptolemos JP, Büchler MW, Belka C, Boeck S, Lerch MM, Mayerle J. Mahajan UM, et al. Among authors: kruger s. JNCI Cancer Spectr. 2019 Aug 16;4(1):pkz060. doi: 10.1093/jncics/pkz060. eCollection 2020 Feb. JNCI Cancer Spectr. 2019. PMID: 32296755 Free PMC article.
Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer - translational results from the AIO-PK0104 Phase 3 study.
Guenther M, Haas M, Heinemann V, Kruger S, Westphalen CB, von Bergwelt-Baildon M, Mayerle J, Werner J, Kirchner T, Boeck S, Ormanns S. Guenther M, et al. Among authors: kruger s. Br J Cancer. 2020 Oct;123(9):1370-1376. doi: 10.1038/s41416-020-01029-7. Epub 2020 Aug 24. Br J Cancer. 2020. PMID: 32830200 Free PMC article.
Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method.
Haas M, Waldschmidt DT, Stahl M, Reinacher-Schick A, Freiberg-Richter J, Fischer von Weikersthal L, Kaiser F, Kanzler S, Frickhofen N, Seufferlein T, Dechow T, Mahlberg R, Malfertheiner P, Illerhaus G, Kubicka S, Abdul-Ahad A, Snijder R, Kruger S, Westphalen CB, Held S, von Bergwelt-Baildon M, Boeck S, Heinemann V. Haas M, et al. Among authors: kruger s. Eur J Cancer. 2021 Mar;146:95-106. doi: 10.1016/j.ejca.2020.12.029. Epub 2021 Feb 12. Eur J Cancer. 2021. PMID: 33588150 Clinical Trial.
Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Sams L, Kruger S, Heinemann V, Bararia D, Haebe S, Alig S, Haas M, Zhang D, Westphalen CB, Ormanns S, Metzger P, Werner J, Weigert O, von Bergwelt-Baildon M, Rataj F, Kobold S, Boeck S. Sams L, et al. Among authors: kruger s. Clin Transl Oncol. 2021 Nov;23(11):2394-2401. doi: 10.1007/s12094-021-02620-x. Epub 2021 Apr 19. Clin Transl Oncol. 2021. PMID: 33876417 Free PMC article.
T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours.
Lesch S, Blumenberg V, Stoiber S, Gottschlich A, Ogonek J, Cadilha BL, Dantes Z, Rataj F, Dorman K, Lutz J, Karches CH, Heise C, Kurzay M, Larimer BM, Grassmann S, Rapp M, Nottebrock A, Kruger S, Tokarew N, Metzger P, Hoerth C, Benmebarek MR, Dhoqina D, Grünmeier R, Seifert M, Oener A, Umut Ö, Joaquina S, Vimeux L, Tran T, Hank T, Baba T, Huynh D, Megens RTA, Janssen KP, Jastroch M, Lamp D, Ruehland S, Di Pilato M, Pruessmann JN, Thomas M, Marr C, Ormanns S, Reischer A, Hristov M, Tartour E, Donnadieu E, Rothenfusser S, Duewell P, König LM, Schnurr M, Subklewe M, Liss AS, Halama N, Reichert M, Mempel TR, Endres S, Kobold S. Lesch S, et al. Among authors: kruger s. Nat Biomed Eng. 2021 Nov;5(11):1246-1260. doi: 10.1038/s41551-021-00737-6. Epub 2021 Jun 3. Nat Biomed Eng. 2021. PMID: 34083764 Free PMC article.
930 results